تنبيه سريري تجريبي

إخلاء مسؤولية: هذه المنصات هي عمل شخصي للدكتور علي الإبراهيم، وهي في المرحلة التجريبية (بيتا) وقد تحتوي على أخطاء. يرجى الإبلاغ عن أي أخطاء أو مقترحات للتحسين إلى Alioud16@gmail.com

الغرض من الأداة ومصادرها وحدودها

مراجعة نتائج NIPT وفق ACOG 2026 وSMFM 2025، مع توضيح الاحتمالات ومصادرها وخيارات العينات والفحوص التشخيصية ومتابعة النتائج غير الحاسمة أو المتعارضة.

منصة مهنية في مرحلة بيتا. راجع المصادر ونطاق النموذج والوحدات قبل تفسير النتائج. لا يعني التحقق البرمجي اعتماداً سريرياً.

طرق الاستخدام ومعايير الأدلة ↗
PRENATAL GENETICS · SIGNAL, SAMPLING & SHARED DECISIONS

NIPT Abnormal Results

Understand the signal.
Make the next step clear.

ACOG 2026 · SMFM 2025 · RCOGClinical approval pending
CLINICAL ENTRY

Clinical detail. Clear priorities.

Tab moves forward; Shift+Tab returns. Enter advances text / number fields. Native select and Space keys are preserved. Ctrl / ⌘ + Enter reviews.

1 · Pregnancy & priorities0 recorded

Use the current clinical context. No age, gestation, singleton status or normal findings are prefilled. Age is descriptive—not an automatic prevalence lookup.

Arrange prompt specialist coordination; this tool does not calculate legal deadlines or determine which pregnancy options are available.
Clinical instability, significant bleeding, severe pain or another acute concern requires clinical assessment—not a genetic probability score.
2 · Original laboratory report0 recorded

Transcribe the actual wording and assay. A z-score, sensitivity or “high risk” label is not a PPV. Verify the report after completing transcription.

Record exactly as reported. No universal 3.5% / 4% validity threshold is imposed.
3 · Ultrasound & phenotype0 recorded

Describe the phenotype without multiplying guessed likelihood ratios into the prior. A normal scan does not exclude a genetic diagnosis, and a low-risk cfDNA result does not explain a structural anomaly.

Record CRL / GA and technique in the notes. NT is not used as an invented numerical risk multiplier.
4 · Discordance & maternal sources0 recorded

Fetal, placental, maternal and technical explanations may coexist. A finding here is a context flag, not proof of the cause or an automatic cancer diagnosis.

5 · Probability & assumptions0 recorded

Optional, source-documented counselling aid. No age table, fixed rare-condition prevalence or default assay performance. Complex / nonreportable results never receive an ordinary PPV / NPV.

6 · Diagnostic sampling & choice0 recorded

Choose the question, specimen and timing together. These are counselling prompts, not procedural clearance, a booking or consent.

7 · Assays & result reconciliation0 recorded

No generic test excludes every condition. Record the actual specimen, assay scope and specialist interpretation. A normal result is not automatically proof of a false-positive screen.

8 · Counselling & follow-up0 recorded

A tracker documents user-recorded progress; the workbench never sends referrals or auto-attests that counselling, consent or a test has occurred.

A SIGNAL · A CONVERSATION · A CONFIRMATION PLAN

Start with the original result

Keep the result, its limits and the next step in the same conversation.

CURRENT CONTEXTNot recordedNot assessed / unknown
REPORTED RESULTNot enteredNot assessed / unknown
NUMERICAL COUNSELLINGNot establishedNo default percentages
4 unresolved assessment items
  • Select the actual reported result category.
  • Pregnancy type / chorionicity is not assessed.
  • Ultrasound phenotype is unverified / not yet assessed; do not infer normal anatomy.
  • Vanishing / demised co-twin context is unknown, not automatically absent or present.

Screening is not a fetal diagnosis

No pregnancy decision, diagnosis, consent, referral or completed test is inferred. Diagnostic sampling and the laboratory assay answer related—but different—questions.

No valid current case report available.

New case entries stay in this page’s memory; no case storage or transmission is introduced. Reload / reset clears the current in-memory case. Saved cases from previous versions are not loaded. Copied, exported and printed records remain under your control.

Clear this input section?

Fields in this section return to blank / unknown. Other sections remain; verify the retained context and planning details. The handover acknowledgement will be cleared.

From screening signal to a clear plan

100%
Educational flow diagram separating screen-positive, no-call / complex, and low-risk cfDNA results. Each route leads to appropriate laboratory clarification, counselling and ultrasound. Diagnostic options depend on target, phenotype and gestation, then specimen-specific interpretation and a named follow-up plan.

No-call is not low risk. A structural finding still needs assessment after a low-risk screen. Every route preserves patient choice and the difference between screening and diagnosis.

Educational illustrations · Educational only · Not to scale · Clinical approval pending.

معلومات المنصة والمراجع

Version: 2.0 local review
Guideline version: ACOG January 2026; SMFM #74 (2025); RCOG GTG8; SMFM #41 / #42 / #57
Last reviewed date: 20 October 2026
Formula source: Bayes theorem with explicitly sourced prior / sensitivity / specificity; expected-count teaching model
Coefficient source: No age-based prior, rare-target placeholder performance or clinical-marker multipliers
Validation notes: Local automated / browser verification; independent MFM / prenatal genetics / cytogenetics approval required
Known limitations: Screening is not diagnosis. No-call / complex results have no ordinary PPV. Selected pathways are not a complete genetic assessment, local legal rule, procedural clearance or universal screening policy.
What changed in this version: Controlled React rebuild; current guidance; no invented risk multipliers; specimen / assay-specific diagnostics; no-call and maternal / placental pathways; source-gated probability explanation; four current-case drafts; keyboard / reset workflow; educational diagrams.
© 2026 Dr. Ali Hussein Al Ibrahim. All rights reserved.